Vaccinations in practice

Michał Wronowski

Department of Pediatrics with Assesment Unit

DOWNLOAD ME!!!

https://tiny.pl/7rfzg

Reliable info – where to find?



DZIENNIK URZĘDOWY
MINISTRA ZDROWIA

Warszawa, dnia 16 października 2019 r.

Poz. 87

Elektronicznie podpisany przez:
Marcin Ciężki
Data: 16.10.2019 14:34:49

KOMUNIKAT
GŁÓWNEGO INSPEKTORA SANITARNEGO

z dnia 16 października 2019 r.

w sprawie Programu Szczepień Ochronnych na rok 2020

Na podstawie art. 17 ust. 11 ustawy z dnia 5 grudnia 2008 r. o zapobieganiu oraz zwalczaniu zakażeń i chorób zakaźnych u ludzi (Dz. U. z 2019 r. poz. 1239 i 1495) ogłasza się Program Szczepień Ochronnych na rok 2020, który stanowi załącznik do niniejszego komunikatu.

Główny Inspektor Sanitarny

Jarosław Pinkas

EU - ECDC

Vaccine schedules in all countries of the European Union

Quick search

Country: -- Select a country --

Age group: ☑ Child ☑ Adult

View schedule

Advanced search

Immunisation schedules by target disease

Disease: -- Select a disease --

In: All EU countries

View schedule

Compare national immunisation schedules

Compare: -- Select a country --

With: -- Select a country --

Age group: ☑ Child ☑ Adult

View schedule

- Immunisation and vaccines
- Vaccine-preventable diseases
- Childhood immunisation
- Vaccine hesitancy
- Vaccine safety
- Vaccine efficacy / effectiveness
- Vaccination coverage
- **EU vaccination schedules**
- Immunisation Information Systems
- European Immunisation Week
- Communication
- Infographics and videos

ACIP


https://www.cdc.gov/vaccines/acip/index.html
CDC Centers for Disease Control and Prevention
CDC 24/7: Saving Lives, Protecting People™
All A-Z
Search
Vaccines site
Advanced Search
Advisory Committee on Immunization Practices (ACIP)
Updated Recommendations for Tdap Vaccination
The COVID-19 pandemic is changing rapidly and requires different strategies to maintain clinical preventive services, including immunization. Find up-to-date guidance on childhood, adult, and maternal vaccination and clinical practice.
The June 24, 2020 ACIP Meeting will be a virtual meeting with no in-person attendance. All details will be posted to this website around June 1, 2020.
Agenda [PDF – 113 KB]
ACIP Meeting Information
ACIP Committee Information
ACIP Committee Members

European Medicines Agency



European Medicines Agency - EPAR

- EMA publishes detailed information on the medicines assessed by the Committee for Medicinal Products for Human Use (CHMP) and Committee for Medicinal Products for Veterinary Use (CVMP)
- The main vehicle for this information is known as a European public assessment report

Summary of product charecteristics

Bexsero Meningococcal Group B vaccine for injection in pre-filled syringe

Summary of Product Characteristics Updated 15-May-2020 | GlaxoSmithKline UK

1. Name of the medicinal product

Bexsero suspension for injection in pre-filled syringe

Meningococcal group B Vaccine (rDNA, component, adsorbed)

2. Qualitative and quantitative composition

One dose (0.5 ml) contains:

Recombinant *Neisseria meningitidis* group B NHBA fusion protein [1, 2, 3]	50 micrograms
Recombinant *Neisseria meningitidis* group B NadA protein [1, 2, 3]	50 micrograms
Recombinant *Neisseria meningitidis* group B fHbp fusion protein [1, 2, 3]	50 micrograms
Outer membrane vesicles (OMV) from *Neisseria meningitidis* group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4 [2]	25 micrograms

[1] produced in *E. coli* cells by recombinant DNA technology

[2] adsorbed on aluminium hydroxide (0.5 mg Al^{3+})

[3] NHBA (Neisserial Heparin Binding Antigen), NadA (*Neisseria* adhesin A), fHbp (factor H binding protein)

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Suspension for injection.

White opalescent liquid suspension.

4. Clinical particulars

EPAR – check for changes!



Vaccination schedule



One visit – one vaccination? Check!

4.5 Interaction with other medicinal products and other forms of interaction

Use with other vaccines

Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines: diphtheria, tetanus, acellular pertussis, *Haemophilus influenzae* type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella, varicella, and meningococcal groups A, C, W, Y conjugate.

Clinical studies demonstrated that the immune responses of the co-administered routine vaccines were unaffected by concomitant administration of Bexsero, based on non-inferior antibody response rates to the routine vaccines given alone. Inconsistent results were seen across studies for responses to inactivated poliovirus type 2 and pneumococcal conjugate serotype 6B and lower antibody titers to the pertussis pertactin antigen were also noted, but these data do not suggest clinically significant interference.

Due to an increased risk of fever, tenderness at the injection site, change in eating habits and irritability when Bexsero was co-administered with the above vaccines, separate vaccinations can be considered when possible. Prophylactic use of paracetamol reduces the incidence and severity of fever without affecting the immunogenicity of either Bexsero or routine vaccines. The effect of antipyretics other than paracetamol on the immune response has not been studied.

Concomitant administration of Bexsero with vaccines other than those mentioned above has not been studied.

When given concomitantly with other vaccines Bexsero must be administered at separate injection sites (see section 4.2).


5:43
Szczepienia dla pr...
Nowa aktywność
Sortuj
1 godz. •
Proszę o rozszyfrowanie przeciw czemu jest to wpisane w ukraińską książeczkę szczepienie...
Тип щепл.
Препарат Vaccine
Дата Date
Серія Lot #
Підпис, печатка лікаря (ЛПЗ) Signature and stamp
P. Matry
Komentarze: 17

Types of vaccines:

- Live-attenuated **vaccines**.
- Inactivated **vaccines**.
- Subunit, recombinant, polysaccharide, and conjugate **vaccines**.
- Toxoid **vaccines**.

} killed

Intervals between different vaccines

- attenuated ↔ attenuated
  - On the same day or >28 days
  - If two live **vaccines** are not given on the same day and are given less than four weeks apart, the second **vaccine** should be repeated

- attenuated ↔killed – no interval required
- Killed ↔killed - no interval required

Intervals between vaccine doses



Wszystko | Grafika | Wiadomości | Filmy | Zakupy | Więcej | Ustawienia | Narzędzia

Około 11 000 000 wyników (0,42 s)

TABLE 3-1. Recommended and minimum ages and intervals between vaccine doses (a),(b),(c),(d)

Vaccine and dose number	Recommended age for this dose	Recommended **interval** to next dose
Influenza, inactivated(o)	≥6 months	4 weeks
IPV-1(e)	2 months	8 weeks
IPV-2	4 months	8 weeks-14 months
IPV-3	6-18 months	3-5 years

Jeszcze 33 wiersze

www.cdc.gov › vaccines › hcp › acip-recs › general-recs

ACIP Timing and Spacing Guidelines for Immunization - CDC

Intervals between vaccine doses

- Doses of any vaccine administered ≥5 days earlier than the minimum interval or age should not be counted as valid doses and should be repeated as age appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval
- For example, if the first and second doses of *Haemophilus influenzae* type b (Hib) were administered only 14 days apart, the second dose would be invalid and need to be repeated because the minimum interval from dose 1 to dose 2 is 4 weeks. The repeat dose should be administered ≥4 weeks after the invalid dose (in this case, the second). The repeat dose is counted as the valid second dose.

Dea


Measles, Mump
Priorix®


Vivotif®
Live vaccine against typhoid fever
3 enteric-coated capsules
Store under refrigeration
Ubat Terkawal / Controlled Medicine
Reg. No.: MAL19871585AZ
PaxVax


STRAINS
4
SANOFI PASTEUR

Odstępy czasowe między kolejnymi dawkami tej samej szczepionki

Odstępy czasowe między kolejnymi dawkami tej samej szczepionki

Tabela 1. Zalecany optymalny i minimalny wiek oraz zalecane i minimalne odstępy czasu pomiędzy kolejnymi dawkami rutynowo stosowanych szczepionek[a-c]

Szczepionka i numer dawki	Zalecany wiek dla podania tej dawki	Minimalny wiek dla podania tej dawki	Zalecany odstęp do podania kolejnej dawki	Minimalny odstęp do podania kolejnej dawki
HepB-1[c]	w ciągu 24 h po urodzeniu	w ciągu 24 h po urodzeniu	1–4 miesięcy	4 tygodnie
HepB-2	1–2 miesięcy	4 tygodnie	2–17 miesięcy	8 tygodni
HepB-3[d]	6–18 miesięcy	24 tygodnie	–	–
(DTPa, DTPw)-1[c]	2 miesiące	6 tygodni	2 miesiące	4 tygodnie
(DTPa, DTPw)-2	4 miesiące	10 tygodni	2 miesiące	4 tygodnie
(DTPa, DTPw)-3	6 miesięcy	14 tygodni	6–12 miesięcy[e]	6 miesięcy[e,f]
(DTPa, DTPw)-4	15–18 miesięcy	12 miesięcy	3–4 lata	6 miesięcy[e]
DTPa-5	4–6 lat	4 lata	–	–
Hib-1[c,g]	2 miesiące	6 tygodni	2 miesiące	4 tygodnie
Hib-2	4 miesiące	10 tygodni	2 miesiące	4 tygodnie
Hib-3h	6 miesięcy	14 tygodni	6–9 miesięcye	8 tygodni
Hib-4	12–18 miesięcy	12 miesięcy	–	–
IPV-1[c]	3–4 miesięcy	6 tygodni	2 miesiące	4 tygodnie
IPV-2	5–6 miesięcy	10 tygodni	2–14 miesięcy	4 tygodnie
IPV-3	16–18 miesięcy	14 tygodni	3–5 lat	4 tygodnie
IPV-4	4–6 lat	18 tygodni	–	–

TABLE 6–1. Dose and route of administration for selected vaccines

Vaccine	Dose	Route
DTaP, DT, Td, Tdap	0.5 mL	IM
DTaP-HepB-IPV	0.5 mL	IM
DTaP/Hib	0.5 mL	IM
DTaP-IPV/Hib	0.5 mL	IM
DTaP-IPV	0.5 mL	IM
Hib	0.5 mL	IM
Hib-MenCY	0.5 mL	IM
HepA	≤18 years: 0.5 mL ≥19 years: 1.0 mL	IM
HepB	≤19 years: 0.5 mL[(a)] ≥20 years: 1.0 mL	IM
HepA-HepB	≥18 years: 1.0 mL	IM
LAIV	0.2 mL divided dose between nares	Intranasal spray

Injection types



Intramuscular injection

IM site for children (after the 1st birthday) and adults



Insert needle at a 90° angle into thickest portion of deltoid muscle—a
the level of the axilla and below the acromion.

IM site for infants

Insert needle at a 90° angle into the anterolateral thigh muscle.

Intramuscular injection

TABLE 6–2. Needle length and injection site of IM injections for children aged ≤18 years (by age) and adults aged ≥19 years (by sex and weight)

Age group	Needle length	Injection site
Children (birth-18 years)		
Neonates[a]	5/8 inch (16 mm)[b]	Anterolateral thigh
Infants, 1-12 months	1 inch (25 mm)	Anterolateral thigh
Toddlers, 1-2 years	1-1.25 inch (25-32 mm)	Anterolateral thigh[c]
	5/8[b]-1 inch (16-25 mm)	Deltoid muscle of arm
Children, 3-10 years	5/8[b]-1 inch (16-25 mm)	Deltoid muscle of arm[c]
	1-1.25 inches (25-32 mm)	Anterolateral thigh
Children, 11-18 years	5/8[b]-1 inch (16-25 mm)	Deltoid muscle of arm[c]
	1-1.5 inches (25-38 mm)	Anterolateral thigh

Subcutaneous injection



Multiple injections?

- DTP
- menB
- menACWY
- PCV13
- hepB

?



Time to practice!